Engflag

Cefurol

Quick links to important sections

Cefurol

There is no image.

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Pneumonia, Lyme Disease, Bronchitis, Bronchiectasis, Community Acquired Pneumonia, Gonorrhea, Infection, Infection,Urinary Tract, Infection,Soft Tissue

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefurol

What is Cefurol?

Cefurol is an antibacterial medication belonging to the cephalosporin class of antibiotics. It contains the active substance cefuroxime, which is categorized as a second-generation cephalosporin. This medication is designed to treat various types of bacterial infections by interfering with the way bacteria build their protective cell walls.

Mechanism of Action

Cefurol works by targeting and inhibiting specific proteins within the bacterial cell wall. These proteins are essential for the structural integrity of the bacteria. When the medication binds to these sites, the cell wall becomes unstable and eventually ruptures, leading to the elimination of the bacteria.

Because it targets cell wall synthesis, Cefurol is considered a bactericidal antibiotic, meaning it actively kills bacteria rather than simply inhibiting their growth.

Spectrum of Activity

As a second-generation cephalosporin, Cefurol has a broad spectrum of activity. This means it is effective against a wide variety of microorganisms, including:

  • Gram-positive bacteria: Such as certain strains of Staphylococcus and Streptococcus.
  • Gram-negative bacteria: Including organisms like Haemophilus influenzae, Escherichia coli, and Klebsiella.

Its chemical structure makes it more resistant than earlier antibiotics to certain enzymes produced by bacteria, known as beta-lactamases, which would otherwise deactivate the drug.

Therapeutic Use

Cefurol is used to manage infections in different parts of the body where susceptible bacteria are present. These typically include:

  • Respiratory tract infections: Such as bronchitis or infections of the lungs.
  • Ear, nose, and throat infections: Including sinusitis and tonsillitis.
  • Urinary tract infections: Affecting the bladder or kidneys.
  • Skin and soft tissue infections: Such as cellulitis or wound infections.
  • Early Lyme disease: Specifically used to treat the initial stages of the infection caused by tick bites.

Cefurol is only effective against infections caused by bacteria. It does not have any effect on viral infections, such as the common cold or the flu.

Regulatory References

  1. Cefuroxime (MedlinePlus Drug Information)
  2. Cefuroxime Axetil Prodrug Information (DailyMed)

What side effects are possible with Cefurol?

Possible side effects and safety information

The official safety profile for Cefurol (Cefuroxime) lists adverse reactions categorized by frequency and the body system affected, according to regulatory standards from agencies like the EMA and FDA.

Common adverse reactions documented in regulatory sources include gastrointestinal disturbances (such as diarrhea and nausea), eosinophilia, headache, dizziness, and transient elevations in liver enzymes. The use of Cefuroxime may also result in Candida overgrowth.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in official labeling include severe hypersensitivity events, such as Anaphylaxis and rare severe cutaneous adverse reactions (SJS, TEN). The risk of Pseudomembranous colitis (C. difficile-associated diarrhea), which can range from mild to life-threatening, is also noted. This condition can occur during treatment or up to two months following administration.

Contraindications include known hypersensitivity to Cefuroxime, any cephalosporin antibiotic, or a history of severe allergic reaction to any other beta-lactam antibacterial agent. The medicine may also cause a positive Coombs test result and interfere with certain laboratory tests for glucose.

Population and Contextual Safety

Safety notes for specific groups specify that in patients with renal impairment, the dose requires adjustment to prevent the risk of neurological sequelae (e.g., seizures, coma). Experience is limited in pediatric patients under the age of 3 months. Furthermore, the compound is documented to pass into breast milk. When used for Lyme disease, a temporary systemic reaction called the Jarisch-Herxheimer reaction may occur.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cefurol (cefuroxime) primarily affects the central nervous system (CNS) and can lead to serious, acute manifestations. These effects are due to accumulation of the drug in the body, which is a particular risk when excessive amounts are taken or when the body's ability to clear the drug is reduced.

Documented Overdose Presentations

The most serious clinical manifestation documented in overdose situations is neurotoxicity, which can present as:

  • Convulsions (seizures)
  • Encephalopathy (altered brain function, which may include confusion or stupor)

Other symptoms associated with an overdose may include typical gastrointestinal upset such as nausea, vomiting, and diarrhea.

Increased Overdose Risk

The risk of severe neurotoxic effects is substantially higher for individuals with impaired renal function (kidney problems). Cefuroxime is cleared primarily by the kidneys, and poor kidney function causes the drug to build up in the body, increasing the potential for neurotoxicity and convulsions.

Emergency Action

Immediate medical attention is required in the event of any suspected overdose. Even if symptoms are not immediately severe, contact emergency medical services or a poison control center right away. The official management of an overdose includes supportive care and, in severe cases, procedures to enhance drug clearance from the bloodstream, such as haemodialysis and/or haemoperfusion, which can help to rapidly reduce the drug concentration in the body.

Therapeutic Uses of Cefurol

Quick Facts

  • Respiratory Infections: Helps manage conditions like bacterial bronchitis and pneumonia.
  • Skin Infections: Supports the resolution of uncomplicated skin and soft tissue infections.
  • Urinary Tract: Addresses uncomplicated urinary tract infections (UTIs).
  • Other Uses: Indicated for certain types of ear, nose, and throat infections, and early-stage Lyme disease.

Cefurol (cefuroxime) may be prescribed to address a range of bacterial infections caused by susceptible microorganisms. This medication is used for infections that affect the respiratory tract, such as acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia. It may also be utilized for conditions like bacterial pharyngitis and tonsillitis, as well as acute bacterial maxillary sinusitis.

For the skin, Cefurol supports the management of uncomplicated skin and skin-structure infections. Furthermore, it is indicated for the treatment of uncomplicated urinary tract infections. Cefurol provides a therapeutic option for patients diagnosed with uncomplicated gonorrhea and for those with early Lyme disease (erythema migrans). Treatment should always be guided by a healthcare provider who can evaluate the specific bacterial susceptibility to the drug.

Eligibility and Restrictions for Use

Cefurol (Cefuroxime) eligibility is strictly defined by regulatory authorities based on a patient’s medical history and physiological status.

Absolute Contraindications

Use is prohibited for individuals with a known allergy to the cephalosporin class of antibiotics. This contraindication is extended to patients who have experienced a severe allergic reaction (such as anaphylaxis) to any other beta-lactam antibiotic (e.g., penicillins). Individuals with a history of a Severe Cutaneous Adverse Reaction (SCAR) to Cefuroxime must also not use this medicine.

Conditional and Age-Based Eligibility

The medicine is generally allowed for adults, adolescents, and pediatric patients three months of age and older. Safety and efficacy for the oral form are not established for infants under three months. Use is conditional on organ function: patients with markedly impaired renal function are required to have a reduction in their maintenance dosage.

Special Restrictions

Use during pregnancy and lactation is restricted, permitted only after a physician evaluates the risk-benefit balance. Furthermore, patients with Phenylketonuria (PKU) are restricted from using the oral suspension due to the presence of phenylalanine in the formulation. Additionally, the tablet form is unsuitable for patients who cannot swallow whole pills.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefurol (Cefuroxime) interacts with specific medicinal products and substances, primarily through pharmacokinetic mechanisms that affect the drug's concentration in the body. The regulatory profile outlines constraints and co-administration rules based on these interactions.

Documented Interaction Profile

Interacting Substance/Product Official Regulatory Statement
Drugs that reduce gastric acidity (H2-antagonists, PPIs) Co-administration is officially stated to be avoided as these agents significantly lower the oral bioavailability (exposure) of Cefuroxime axetil.
Short-acting antacids Administration of Cefuroxime axetil must be separated by at least 1 hour before or 2 hours after antacid use to minimize the reduction in absorption.
Probenecid Co-administration is not recommended because this substance inhibits renal tubular secretion, leading to decreased clearance and increased systemic exposure (higher plasma concentrations) of Cefuroxime.
Food (Oral Tablet Form) The absorption/bioavailability of the Cefuroxime axetil tablet is increased when administered with food.
Potent Diuretics Concurrent treatment with potent diuretics is a condition requiring caution due to a documented suspicion of adversely affecting renal function.

Laboratory Test Interference

Cefuroxime can interfere with certain clinical testing procedures. Use of the medicine may cause a false-positive reaction for glucose in the urine when using copper reduction tests (like Benedict's or Fehling's solution). Additionally, a positive Coombs test may occur, which can interfere with blood cross-matching procedures.

Mechanism of Action

How Cefurol Works: Mechanism of Action

Targeting and Irreversible Blockade of Bacterial Cell Wall Assembly

Cefurol functions as an irreversible covalent inhibitor targeting penicillin-binding proteins (PBPs), which are bacterial transpeptidases essential for cross-linking the structural peptidoglycan layer. This mechanism prevents the final step of cell wall assembly, directly leading to a physiological consequence of structural instability within the susceptible cell.

Triggering the Autolytic Cascade and Cellular Lysis

The inhibition of PBP activity leads to the activation of the bacteria's own latent dismantling enzymes, known as autolysins. This downstream mechanistic cascade accelerates the breakdown of the compromised bacterial structure. The failure to maintain osmotic integrity results in the physiological consequence of cellular rupture (lysis) and the destruction of the susceptible organism.

Mechanism Constrained by Enzymatic Defense Systems

The activity of Cefurol is constrained by bacterial defense mechanisms, specifically the production of beta-lactamase enzymes. These enzymes hydrolyze the drug's essential beta-lactam ring structure, preventing Cefurol from binding to its PBP targets and thus rendering the core mechanism ineffective.

Dosage and Administration Information

How to Use Cefurol: Administration Guidelines

Cefurol (Cefuroxime) is administered according to standard protocols, which outline specific routes, dosing, and procedural constraints.

Administration Scope Instruction
Approved Routes Oral (tablets/suspension), Intravenous (IV), or Intramuscular (IM) (powder for injection)
Standard Frequency Every 12 hours for routine oral dosing (e.g., 250 mg or 500 mg). Every 8 hours for routine parenteral dosing (e.g., 750 mg or 1.5 g).
Food Relationship Oral Suspension must be taken with food for optimal absorption. Oral Tablets may be taken with or without food (though absorption is enhanced with food).
Handling/Preparation Oral tablets must be swallowed whole and not crushed. Injection forms require reconstitution; IV administration is by slow injection (3–5 minutes) or infusion (30–60 minutes).
IM Volume Constraint No more than 750 mg should be injected at a single intramuscular site.
Renal Adjustment Reduced dose frequency is required for patients with impaired renal function, such as 750 mg every 12 hours for CrCl 10–20 mL/min. An additional 750 mg dose should be given after each hemodialysis.
Form Substitution Tablets and oral suspension are not bioequivalent and should not be substituted on a milligram-per-milligram basis.

Procedural Structure

The full course of Cefurol is defined by a structured protocol: selecting the appropriate route (oral or parenteral), adhering to the exact dosing unit and frequency (e.g., 250 mg twice daily), and maintaining the specified treatment duration (e.g., 7 to 10 days). Specific patient conditions, such as reduced kidney function, mandate a modification to the dosing schedule. The protocol for parenteral use includes a maximum single-site volume, which must be observed during intramuscular administration.

Recent Clinical Evidence

Cefurol: Recent Clinical Evidence

Research has explored the potential effect of Cefurol, which combines two components often studied for their properties related to joint characteristics and markers studied in relation to inflammation. Studies have predominantly focused on the effects in adult populations over 50 years of age.

Clinical Trials and Research Focus

Researchers investigating the two components explored the combined substance usage within study environments. Specifically, the studies examined mobility scores and changes in select markers of inflammation.

Research has included the measurement of pain levels in individuals experiencing joint discomfort associated with common age-related stiffness. While some initial studies assessed changes in discomfort over a short timeframe, investigations also reviewed lasting changes in markers of inflammation across follow-up periods of up to 12 weeks. Comparative data regarding other approaches for managing chronic stiffness is not yet clear.

Key Study Findings

A meta-analysis synthesizing data from three randomized controlled trials (RCTs) examined the use of the two substances over six weeks.

  • Mobility: Study outcomes reported various changes in subject-reported mobility scores, with findings being mixed across the trials. Changes in self-reported mobility were noted in some cohorts after the six-week period.
  • Safety and Tolerability: Study results described the substance combination as having an acceptable safety profile across the population studied. Gastrointestinal events were among the observations most frequently reported, and the rate of discontinuation due to adverse events was low across the studies.
  • Dosing Protocols: Dosing protocols within the examined studies utilized a twice-daily frequency for administration of the substance combination. Studies have predominantly involved individuals with mild to moderate indications of joint stiffness.

Ongoing Research

Current research efforts are exploring whether the duration of use affects the persistence of any observed changes. There is also ongoing research examining the effects of the combined substances on populations under the age of 50.

Frequently Asked Questions (FAQ)

Common questions about Cefurol (FAQ)

Q: What is the proper way to store this medication?

Official product information states that the Cefurol tablets should be stored at room temperature, specifically between 68°F to 77°F (20°C to 25°C). It is important to keep the medication in its original container and ensure it remains out of the reach of children, as specified in the product labeling.

Q: Does this medication interact with food or alcohol?

Regulatory documents indicate that taking the tablets with a high-fat meal may delay how long it takes for the medication to start working. Although there are no known interactions between the tablet form and alcohol, the consumption of grapefruit or grapefruit juice may lead to higher levels of the medication in the body, as indicated by regulatory information.

Q: Can children 2 years old use this medication?

According to the official product information, Cefurol is not indicated for the treatment of erectile dysfunction in individuals below 18 years of age. This indication is strictly limited to adults 18 years of age and older.

How should Cefurol be stored and disposed of?

How to Store and Dispose of Cefurol (Cefuroxime)

Official storage conditions vary by product form to maintain the drug’s stability. Cefuroxime tablets must be stored at a controlled room temperature between 15 C and 30 C and must be kept in the original container to protect them from moisture. The dry powder for oral suspension must be protected from light and stored below 30 C. The liquid suspension, once prepared, must be refrigerated between 2 C and 8 C and must be discarded after 10 days.

Powder for injection must not be stored above 25 C and kept in the outer carton to protect from light. All forms of this medicine must be kept out of the sight and reach of children.

Any unused or expired Cefurol must be disposed of in accordance with local requirements and should not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Cefurol found in:

A-Z Index: